← Leaderboards
Dina Chelouche Lev
Sarc
$1,262,548
Attributed
$1,262,548
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $262.2K · FY2012–16$500K$375K$250K$125K$0
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$1,262,548 · 1
By mechanism
U54$1,262,548 · 1
Top collaborators
No co-investigators on record.
Most similar at Sarc
Same institution · by research overlap
- Jeffrey T Yap$3,544,474
- Denise Reinke$1,578,628
Others in their field
Top investigators on “Advanced Disease”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$301,322,418
- Lawrence Corey · Fred Hutchinson Cancer Center$280,538,218
- Kiran Datta · Leidos Biomedical Research, Inc.$277,585,346
- Judith S. Currier · University Of California Los Angeles$276,624,848
- Chanza Baytop · Westat, Inc.$271,217,917
Research focus
Advanced DiseaseHeterogeneityAggressive BehaviorApoptosisAneuploidyBaseCell LineCellsChemotherapyChloroquineAutophagocytosisClinical TrialsCohortComplexCytotoxic AgentDoxorubicinEffective TherapyFamilyFusion GeneFutureGene Expression ProfileGrowthClinicHistologic
Grant awards (5)
Histone deacetylase inhibitor (HDACi)-based therapeutic strategies for the treat$248,543
U54 · FY2016 · CA · contact PI
Histone deacetylase inhibitor (HDACi)-based therapeutic strategies for the treat$252,274
U54 · FY2015 · CA · contact PI
Histone deacetylase inhibitor (HDACi)-based therapeutic strategies for the treat$250,845
U54 · FY2014 · CA · contact PI
Histone deacetylase inhibitor (HDACi)-based therapeutic strategies for the treat$248,713
U54 · FY2013 · CA · contact PI
Histone deacetylase inhibitor (HDACi)-based therapeutic strategies for the treat$262,173
U54 · FY2012 · CA · contact PI